Credit Suisse Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $75
Credit Suisse analyst Judah Frommer maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and raises the price target from $72 to $75.
JP Morgan Upgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $87
JP Morgan analyst Anupam Rama upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Underweight to Neutral and lowers the price target from $92 to $87.
Sarepta Therapeutics Q2 EPS $(1.52) Misses $(1.29) Estimate, Sales $141.80M Miss $162.64M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.29) by 17.83 percent. This is a 0.66 percent decrease over losses of $(1.51) per share
Sarepta Therapeutics Earlier Announced Execution Of Licensing Agreement For Gene Therapy Program From Nationwide Children’s Hospital To Treat Limb-Girdle Muscular Dystrophy Type 2A; Financial Details Not Disclosed
– Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses
– Sarepta's unrivaled portfolio of investigational gene
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Support.Com Shares Move Higher On Volume; Traders Circulate Benzinga Report ‘3 Short Squeeze Candidates Trading Under $5’ Mentioning Stock; Article Also Mentions ReShape Lifesciences And Recon Technology
https://www.benzinga.com/trading-ideas/long-ideas/21/07/21981135/3-short-squeeze-candidates-trading-under-5
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
Cathie Wood’s ARK Invest Posts Fund Sales For Thursday, June 17, 2021: TAK, SRPT, PSTI, NVS, GLEO, RAVN
Takeda Pharmaceutical (TAK) - 438,746 Shares
Sarepta Pharmaceuticals (SRPT) - 25,742
Pluristem Therapeutics (PSTI) - 2,500
Novartis (NVS) - 349,532
Galileo Acquisition (GLEO) - 679,335
Raven Industries (RAVN) -